Merck Serono Launches Cyanokit In Japan
This article was originally published in PharmAsia News
On March 19, Tokyo-based Merck Serono Co. launched Cyanokit (hydroxocobalamin) in Japan. Approved by Japan's Ministry of Health in September 2007, Cyanokit treats cyanide poisoning caused by hydrocyanic acid and its derivatives in both adults and children, and it will primarily be distributed to hospitals and emergency care centers. Administrated by intravenous infusion, Cyanokit is commercially available in the U.S. and recently approved in the European Union. Merck Serono applauded the launch of Cyanokit as a key milestone for emergency health professionals in Japan. Cyanide poisoning is primarily caused by smoke inhalation during closed-space structural fires. (Click here for more-Japanese language
You may also be interested in...
This month’s column covers deals announced between 1-23 April 2020.
Celltrion’s Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the WHO.
EU MDR Panel Discussion: Why An Extra Year Is Not Really A Delay For The MDR – How To Survive Changing And Confusing Times
26 May 2020, the date that the Medical Device Regulation was originally due to apply in the EU, was a good time to take stock of where the medtech sector finds itself. Three of the most renowned and outspoken experts on the EU medical device regulatory system gave their views in this exclusive interview.